Ambassador

  • TALKING ABOUT PROGRESSION
  • Getting ahead of ADPKD
  • FROM DENIAL TO DEFIANCE
  • LOOKING AT ADPKD DIFFERENTLY
  • IT’S ALL RELATIVE
  • FROM DIAGNOSIS TO TREATMENT
  • TAKING A STAND
  • HOPE FOR THE FUTURE

Hear from the first generation at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) with a treatment to call their own.

JYNARQUE is a prescription medicine used to slow kidney function decline in adults who are at risk for rapidly progressing ADPKD.

Real patients share their stories.

Talk to your doctor to see if JYNARQUE is right for you.

Scroll to see more

WE ARE GEN 

Real patients share their stories.

Talk to your doctor to see if JYNARQUE is right for you.

TALKING ABOUT PROGRESSION

Knowing what my mom went through, I thought there has to be more to my ADPKD.

Watch

Getting ahead of ADPKD

If I met someone that was at risk for rapidly progressing ADPKD, I would strongly encourage them to begin seeing a nephrologist, and not to wait.

Watch

FROM DENIAL TO DEFIANCE

Because I was in denial for so long, now I want to take charge of my disease. I want to help others and spread awareness. 

Watch

LOOKING AT ADPKD DIFFERENTLY

For many people, ADPKD is a slowly progressing disease, but it doesn't stop progressing on its own.

Watch

IT’S ALL RELATIVE

The history of ADPKD in my family goes back a few generations. There wasn’t much discussion and people didn’t talk about it.

Watch

FROM DIAGNOSIS TO TREATMENT

My doctor said, “Let’s do an ultrasound.” And that’s when they found all of the cysts on my kidneys.

Watch

TAKING A STAND

The treatment means hope for me. It also means that people are investing time and money looking at this disease and finding ways of addressing it.

Watch

HOPE FOR THE FUTURE

JYNARQUE popped on my radar the first day that I met my new nephrologist.

Watch

MORE TO COME

There are more patients with a risk of rapidly progressing ADPKD who want to share their stories. Visit our sign-up page for updates and more information.

COVID-19 UPDATE

With the COVID-19 situation constantly developing, your health is our top priority. We hope that you and your families are staying safe and healthy during this unprecedented time.

If you are currently taking JYNARQUE® (tolvaptan), we encourage you to stay in close contact with your healthcare professional team regarding regular appointments and treatment management plans.

At this time, there is no expected impact on medication supply.

If you have lost a job or health insurance coverage due to the COVID-19 pandemic, we have extended our patient support program to provide "no-cost" access for patients in the U.S. taking JYNARQUE. Please call Otsuka Patient Support at 1-855-242-7787 for more information.

For help accessing JYNARQUE, go to www.otsukapatientsupport.com/jynarque or call Otsuka Patient Support at 1-855-242-7787. The nurses at Otsuka Patient Support can answer questions related to Product Accessibility, Reimbursement and connecting patients to local treatment sites in their community.

Please read FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE.

April 202010US20EBC0044

COVID-19 UPDATE

With the COVID-19 situation constantly developing, your health is our top priority. We hope that you and your families are staying safe and healthy during this unprecedented time.

If you are currently taking JYNARQUE® (tolvaptan), we encourage you to stay in close contact with your healthcare professional team regarding regular appointments and treatment management plans.

At this time, there is no expected impact on medication supply.

If you have lost a job or health insurance coverage due to the COVID-19 pandemic, we have extended our patient support program to provide "no-cost" access for patients in the U.S. taking JYNARQUE. Please call Otsuka Patient Support at 1-855-242-7787 for more information.

For help accessing JYNARQUE, go to www.otsukapatientsupport.com/jynarque or call Otsuka Patient Support at 1-855-242-7787. The nurses at Otsuka Patient Support can answer questions related to Product Accessibility, Reimbursement and connecting patients to local treatment sites in their community.

Please read FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE.

April 202010US20EBC0044